Beta-Thalassemia Disease Pipeline Drugs Assessment: Clinical Trails Analysis, Pl

Posted by saikrishna on May 30th, 2018

Beta-Thalassemia Disease Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018

Overview:

Beta-Thalassemia is an inherited blood disorder characterized by decreased levels of functional hemoglobin, which is the iron containing protein present in red blood cells that carries oxygen to the cells throughout the body. People with Beta-Thalassemia will be suffering from lack of oxygen supply in body and also shortage of red blood cells and will be at the increased risk of developing abnormal blood clots.

Symptoms of Beta-Thalassemia includes pale skin, jaundice, enlarged spleen, liver and heart, delayed puberty. Beta-Thalassemia can be diagnosed by molecular and genetic tests, blood tests etc. Treatment of Beta-Thalassemia includes frequent blood transfusions, bone marrow transplant, surgery to remove spleen or gallbladder and medications.

A sample of this report is available upon request @

https://www.precisionbusinessinsights.com/market-reports/beta-thalassemia-disease-pipeline-drugs-assessment/#ulp-4H8Z4LpNMLEuOnnx

Segmentation:

By Trial Phase, Beta-Thalassemiapipeline drugs are segmented as:

•          Preclinical Trials
•          Phase 1
•          Phase 2
•          Phase 3
•          Phase 4

By Company, Beta-Thalassemiapipeline drugs are segmented as:

•          Celgene Pharmaceuticals
•          bluebird bio.Inc
•          GlaxoSmithKline
•          Acceleron Pharma, Inc.
•          Sanofi
•          Novartis
•          HemaQuest Pharmaceuticals Inc.
•          Hoffmann-La Roche
•          FerroKinBioSciences, Inc.
•          Others

By Drugs, Beta-Thalassemia pipeline drugs are segmented as:

•          LentiGlobin
•          Deferitrin
•          Desferoxamine
•          Bitopertin
•          Deferasirox
•          Luspatercept
•          Zoledronic acid
•          Ambrisentan
•          Others

By Type of Condition, Beta-Thalassemia pipeline drugs are segmented as:

•          Thalassemia Major (Cooley’s anemia)
•          Thalassemia Intermedia

By Route of Administration, Beta-Thalassemiapipeline drugs are segmented as:

•          Oral
•          Parenteral